IL17A and inflammatory bowel disease: The exact mechanism of anti-IL-17 drugs in IBD remains poorly defined, but it is thought that the decrease in IL-17 concentration leads to a reduction in neutrophile aggregation, and thus may enhance gut bacteria overgrowth [67].